Tri Locum Partners’s Evolent Health EVH Stock Holding History

Tri Locum Partners’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-268,011	Closed	-$8.7M	–	70
2023 Q1	$8.7M	Buy	+268,011	New	+$8.48M	2.65%	15
2022 Q3	–	Sell	-324,869	Closed	-$9.98M	–	52
2022 Q2	$9.98M	Buy	324,869 +93,370	+40%	+$2.72M	4.09%	9
2022 Q1	$7.48M	Buy	231,499 +6,402	+3%	+$168K	2.92%	16
2021 Q4	$6.23M	Buy	+225,097	New	+$6.46M	2.45%	16

Other funds holding EVH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Tri Locum Partners's EVH Position: Q2 2023 in Review

Tri Locum Partners sold out of Evolent Health (EVH) in Q2 2023, closing a stake of 268,011 shares — an estimated $8.7M sold.

Tri Locum Partners first reported a position in EVH in Q4 2021 and held it in 4 quarters. The position peaked at $9.98M in Q2 2022. 217 funds tracked by Wall St. Rank hold EVH as of Q2 2023.

Tri Locum Partners reported no remaining Evolent Health position as of Q2 2023 after selling out during the quarter.
Tri Locum Partners sold 268,011 Evolent Health shares in Q2 2023, an estimated $8.7M.
Tri Locum Partners first reported a position in Evolent Health in Q4 2021 and held it in 4 quarters.
Tri Locum Partners's Evolent Health position peaked at $9.98M in Q2 2022.
217 funds tracked by Wall St. Rank held Evolent Health as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.